← Leaderboards
Richard B Pollard
University Of Texas Medical Br Galveston
$5,266,302
Attributed
$5,266,302
Total exposure
18
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $252.5K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$6,800,656 · 19
By mechanism
U01$3,725,626 · 1
P30$1,534,354 · 1
P51$855,989 · 3
M01$684,687 · 13
N01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Lawrence R Stanberry$4,793,012
- William Austin O'Brien$7,154,790
- David P Paar$50,352
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsAids TherapyHuman Therapy EvaluationCombination ChemotherapyDrug Screening /EvaluationAntiaids AgentClinical Trial Phase IPharmacokineticsProtease InhibitorHydroxyureaImmunotherapyInterleukin 2Human Immunodeficiency Virus 12'3'DideoxyinosineStavudineLamivudineAbacavirDrug InteractionsAidsAids VaccinesDosagePatient Oriented Research
Grant awards (36)
NORTH-CENTRAL CALIFORNIA-CENTER FOR AIDS RESEARCH$139,669
P51 · FY2007 · RR · contact PI
NORTH-CENTRAL CALIFORNIA-CENTER FOR AIDS RESEARCH$39,138
P51 · FY2006 · RR · contact PI
NORTH-CENTRAL CALIFORNIA-CENTER FOR AIDS RESEARCH$252,456
P51 · FY2005 · RR
NORTH-CENTRAL CALIFORNIA-CENTER FOR AIDS RESEARCH$424,726
P51 · FY2004 · RR
A TRIAL TO EVALUATE THE ABILITY OF IL-2 TO ENHANCE HIV-SPECIFIC IMMUNITY FOLLOW$33,984
M01 · FY2004 · RR
HIV-1 VACCINES DESIGNED TO INDUCE MUCOSAL IMMUNITY$28,320
M01 · FY2004 · RR
BAY 50-4798 ADMINISTERED IN PATIENTS W/ HIV INFECTION ON HAART COMPARED TO PATIE$8,022
M01 · FY2004 · RR
ATTENUATED STRAIN OF VACCINIA VIRUS ADMINISTERED TO HIV INF INDIV W/ CONTROLLED$7,548
M01 · FY2004 · RR
PHASE I STUDY TO EVALUATE SAFETY OF DERMAVIR, A HIV VACCINE, IN HIV-I SUBJECTS U$7,548
M01 · FY2004 · RR
IMMUNE RECONST W GROWTH HORMONE IN HIV INF SUBJ W/ INCOMPLETE CD4+ LYMPHOCYTE RE$6,474
M01 · FY2004 · RR
North-Central California-Center For AIDS Research$732,522
P30 · FY2003 · AI
North-Central California-Center For AIDS Research$801,832
P30 · FY2002 · AI
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY W/WO RHIL 2 FOR HIV POSITIVE PATIENTS$279,290
M01 · FY2002 · RR
ACTG 384--Protease inhibitor &non-nucleoside reverse transcriptase inhibitor$0
M01 · FY2002 · RR
Safety, pharmacokinetics &effects of calanolide on surrogate markers$0
M01 · FY2002 · RR
Interactions &efficacy of nevirapine, abacavir and amprenavir$0
M01 · FY2002 · RR
Pharmacokinetic study of nine hydroxyurea regimens in combination with ddI &d4T$0
M01 · FY2002 · RR
ACTG 328--HIV/immunogenicity of remune with HAART or HAART &IL2$0
M01 · FY2002 · RR
GW433908 versus amprenavir in subjects with HIV-1 infection$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIAL UNIT$1,842,655
U01 · FY2001 · AI
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY W/WO RHIL 2 FOR HIV POSITIVE PATIENTS$279,290
M01 · FY2001 · RR
GW433908 versus amprenavir in subjects with HIV-1 infection$0
M01 · FY2001 · RR
Interactions &efficacy of nevirapine, abacavir and amprenavir$0
M01 · FY2001 · RR
Safety, pharmacokinetics &effects of calanolide on surrogate markers$0
M01 · FY2001 · RR
ACTG 384--Protease inhibitor &non-nucleoside reverse transcriptase inhibitor$0
M01 · FY2001 · RR
ACTG 328--HIV/immunogenicity of remune with HAART or HAART &IL2$0
M01 · FY2001 · RR
Pharmacokinetic study of nine hydroxyurea regimens in combination with ddI &d4T$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIAL UNIT$1,882,971
U01 · FY2000 · AI
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY W/WO RHIL 2 FOR HIV POSITIVE PATIENTS$34,211
M01 · FY2000 · RR
CLINICAL CENTER FOR VIRAL ACTIVATION TRANSFUSION STUDY$0
N01 · FY2000 · HB
GW433908 versus amprenavir in subjects with HIV-1 infection$0
M01 · FY2000 · RR
ACTG 384--Protease inhibitor &non-nucleoside reverse transcriptase inhibitor$0
M01 · FY2000 · RR
Safety, pharmacokinetics &effects of calanolide on surrogate markers$0
M01 · FY2000 · RR
Interactions &efficacy of nevirapine, abacavir and amprenavir$0
M01 · FY2000 · RR
Pharmacokinetic study of nine hydroxyurea regimens in combination with ddI &d4T$0
M01 · FY2000 · RR
ACTG 328--HIV/immunogenicity of remune with HAART or HAART &IL2$0
M01 · FY2000 · RR